Year None20212020201920182017 Jan 20, 2021 F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 PDF Version Jan 06, 2021 F-star Therapeutics to Participate in Upcoming Conferences PDF Version Jan 04, 2021 F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial PDF Version
